Lupin Share Price

₹ 1,980.70

-₹27.90 (-1.39%)
1D
Last updated 05 Nov, 2026, 10:34 IST
NSE: LUPIN
|
Pharmaceuticals

Lupin Share Price Today

As of 5 Nov 2026, Lupin share price is ₹1,980.70. The stock opened at ₹1,990.00, compared to its previous close of ₹2,008.60. During today's trading session, Lupin share price moved in the range of ₹1,944.10 to ₹1,994.70, with an average price of ₹1,969.40 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,892.90 and a high of ₹2,529.50. On the performance front, Lupin share price has declined by 14.48% over the last six months and is up 0.58% on a year-on-year basis.

Share price over the last 1 day rose from 1962.60 to 1981.80, ranging between 1951.00 and 1985.10.
₹1,944.10
1.39% down today
₹1,994.70
1D LOW
1D HIGH

Lupin Stock Insights

Latest Earning
Op Profit TrendUp by 4.63% QoQ
Latest Earning
Net Profit TrendUp by 61.98% YoY
Latest Earning
Revenue TrendUp by 10.40% QoQ
Stock Performance
OutperformingBeat Nifty by 9.75 % in last 1 year
Shareholding Pattern
PromoterPromoter decreased stake by 0.01%
Shareholding Pattern
DIIDII decreased stake by 6.16%
Shareholding Pattern
FIIFII increased stake by 3.83%
Technical Indicators
Volume SpikeVolume is 50.0% above 20-day average on 1 Day interval.
Technical Indicators
Price breakoutPrice has broken above resistance on 1 Day interval.
Lupin stock performance
Open₹1,990.00
High₹1,994.70
Low₹1,944.10
Prev. close₹2,008.60
Lupin trading activity
Volume4,49,660
Average traded price₹1,965.34
Last traded time10:34:03 05 Nov
Last traded quantity8
Circuit
L
H
₹1,807.80
₹2,209.40
52-week
L
H
₹1,892.90
₹2,529.50
Mkt Cap Cr
92,144.54
P/E
17.65
P/B
3.83
ROA
13.91%
ROE
23.76%
ROCE
24.88%
Quick Ratio
1.42
EV/EBITDA
9.85

Based on fundamentals, this stock's

Performance: 2 out of 5, Poor
Performance
Poor
Lupin has underperformed the market
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Lupin appears overvalued compared to its peers
Earnings: 5 out of 5, Excellent
Earnings
Excellent
Lupin revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,25,150.1638.74.769.61%13.79%18.65%2.3122.17
Divis Laboratories2,64,141.2491.0315.8914.6%15.32%19.56%3.559.98
Torrent Pharmaceuticals1,76,300.5085.729.794.7%11.42%11.37%0.7533.85
Laurus Labs1,25,352.4494.0820.6811.58%22.11%20.91%0.6853.48
Zydus Lifesciences1,18,702.9626.914.568.57%18.59%17.35%0.9116.36
Dr. Reddy's Laboratories1,14,351.2041.442.954.79%7.21%8.58%1.3518.91
Cipla1,12,471.7539.413.186.6%8.18%10.8%2.521.15
Mankind Pharma1,02,315.4046.235.957.82%12.76%14.68%0.7424.84
Aurobindo Pharma97,756.7126.352.586.34%9.25%11.76%1.1512.4
Glenmark Pharma70,608.3839.286.729.03%28.08%32.7%1.2320.09

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Lupin Company Background

ISIN
INE326A01037
Sector Market Cap
₹ 92,144.54 Cr

Established in: 1968

Managing Director: Nilesh Gupta

Lupin Limited is a multinational pharmaceutical company headquartered in Mumbai. The company primarily manufactures generic drugs, and covers therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Lupin Limited operates across multiple international markets such as the United States of America, Japan, Europe and Australia.

Lupin Limited launched its IPO and went public in 1993. The company is listed on the BSE Limited and the National Stock Exchange of India (NSE) under the ticker symbol LUPIN.

History of Lupin Limited

Lupin Limited was established by Desh Bandhu Gupta, professor of chemistry at BITS-Pilani, Rajasthan, in 1968. Desh Bandhu Gupta borrowed 5000 from his family to set up the company. Later, the company obtained funding from the Central Bank of India and established its manufacturing facilities for producing folic acid and iron tablets for the government’s mother and child health initiative.

In the following years, Lupin Limited began manufacturing anti-tuberculosis drugs, which accounted for 36% of the company’s sales. At that point in time, the company was considered the largest TB drugs manufacturer in the world.

In 2016, Lupin Limited acquired Gavis Pharmaceuticals and Novel Laboratories for $880 million. In May 2023, Lupin Limited acquired the French pharmaceutical company Medisol for over Rs 160 crore.

Business Segments of Lupin Limited

The following are the business segments of Lupin Limited.

  • Generic Medicines

The company develops and distributes a wide variety of generic, complex generic and over-the-counter (OTC) medicines and exports them to over 100 countries.

  • Therapeutic Areas

Lupin Limited holds a significant market share in the therapeutic sector and boasts high sales in it, especially in cardiovascular, diabetology, respiratory, paediatrics, and the Central Nervous System.

  • Specialty Pharmaceuticals

The speciality pharmaceutical segment focuses on niche markets with high value, such as women’s health, rare neurological disorders and ophthalmology.

  • Biosimilars

The company researches, manufactures, and distributes high-quality biological medicines through the Lupin Biotech division, aiming to make treatments affordable and accessible around the world.

  • Active Pharmaceutical Ingredients (API)

Lupin Limited is a global manufacturer of APIs, serving both internal pharmaceutical formulations and external drug manufacturers.

  • Global Institutional Business (GIB)

This segment offers affordable and high-quality medications for critical illnesses such as tuberculosis to underserved and impoverished sections of society and international health organisations.

  • Health Services

The company is expanding its operations and entering into modern and adjacent healthcare segments by establishing Lupin Diagnostics, Lupin Digital Health and neuro-rehabilitation centres.

Subsidiaries of Lupin Limited

The following are the subsidiaries of Lupin Limited.

  • Lupin Pharmaceuticals, Incorporated in the USA.
  • Lupin Pharma Canada Limited in Canada.
  • Laboratorios Grin, S.A. de C.V. in Mexico.
  • Medquímica Indústria Farmacêutica LTDA in Brazil.
  • Pharma Dynamics (Proprietary) Limited in South Africa.
  • Nanomi B.V. in the Netherlands.
  • Medisol S.A.S. in France.
  • Lupin Lanka Private Limited in Sri Lanka.

Awards and Recognition Received by Lupin Limited

The following are the awards and recognitions received by Lupin Limited.

  • The company received the Excellence in Patient Support Program by the India Pharma Awards
  • Patient-Centric Pharmaceutical Company of the Year by IHW Patient First Awards
  • Most Innovative Patient Care Initiative by Healthcare Asia Award
  • Best Social Welfare Initiative of the Year by CSR Summit & Awards
  • Lupin Limited won the ATD BEST Award by the Association for Talent Development
  • Received Digital Pharma Marketing Excellence Award by DIGIPHARMAX Conclave
  • The company won the Global Best Project Award of Merit in the Manufacturing Category by Engineering News-Record
  • The company received the Gold Award from the American Society for Quality
  • Lupin Limited won the India Packaging Award for Innovation in Patient Awareness & Design by UBM India

Lupin Financial Highlights

  • Revenue: Lupin reported revenue of ₹28,382.48 crore in FY26 vs ₹22,903.72 crore in FY25. It showed an increase of 23.92% on a yearly basis.
  • Operating Profit: Lupin reported an operating profit of ₹6,872.55 crore in FY26 vs ₹4,015.00 crore in FY25. It showed an increase of 71.17% on a year-on-year basis.
  • Net Profit: Lupin reported a net profit of ₹5,355.47 crore in FY26 vs ₹3,306.26 crore in FY25. It showed an increase of 61.98% on a yearly basis.

Lupin Quarterly Result Highlights

  • Lupin reported revenue of ₹8,407.21 crore in Jun 2026, compared with ₹7,615.37 crore in Mar 2026, representing an increase of 10.40% on a quarter-on-quarter (QoQ) basis.
  • Lupin reported an operating profit of ₹2,017.36 crore in Jun 2026, compared with ₹1,928.00 crore in Mar 2026, representing an increase of 4.63% on a quarter-on-quarter (QoQ) basis.
  • Lupin reported a profit of ₹1,416.98 crore in Jun 2026, compared with ₹1,468.67 crore in Mar 2026, reflecting a decrease of 3.52% on a QoQ basis.
  • The earnings per share (EPS) of Lupin stood at ₹116.75 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
46.85%
FII
23.28%
Other DII
9.20%
Retail and other
6.09%
Mutual funds
14.58%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202521.49%
Mar 202621.71%
Jun 202622.42%
Sep 202623.28%

Lupin Investment Returns

1 day
-0.36%
1 week
+1.82%
1 month
-1.11%
1 year
+0.58%
3 years
+69.28%
5 years
+115.00%

Lupin Share Price History

Lupin share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
04 Nov 26
₹2,025.00 / ₹2,008.60
-0.36%
03 Nov 26
₹2,014.90 / ₹2,015.90
+0.97%
02 Nov 26
₹2,019.80 / ₹1,996.50
-0.72%
30 Oct 26
₹1,995.70 / ₹2,011.00
+1.06%
Show more

Lupin Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹27,958.03₹22,707.90₹20,010.82₹16,641.66
Other Income₹1,080.92₹201.61₹130.68₹150.91
Total Revenue₹29,038.95₹22,909.51₹20,141.50₹16,792.57
Total Expenses₹21,608.49₹18,894.51₹17,719.23₹16,076.08
Profit Before Tax₹6,872.55₹4,015.00₹2,422.27₹716.49
Tax₹1,517.08₹708.74₹486.70₹268.80
Profit After Tax₹5,355.47₹3,306.26₹1,935.57₹447.69
EPS - Basic₹116.75₹71.95₹42.05₹9.46
EPS - Diluted₹116.44₹71.69₹41.87₹9.41

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹6,872.55₹4,015.00₹2,422.27₹716.49
Income before WC changes₹7,968.16₹5,316.52₹3,888.90₹1,813.90
Change in Assets-₹1,813.60-₹1,239.02-₹702.02-₹111.76
Change in Liabilities₹2,447.29-₹171.52₹787.53₹438.28
Change in WC₹633.69-₹1,410.54₹85.51₹326.52
Cash flow from Operations₹7,334.50₹2,999.94₹3,648.36₹1,897.24
Cash flow from Investing-₹3,864.59-₹4,171.89-₹1,712.20-₹1,286.77
Cash flow from Financing-₹845.87₹1,731.88-₹2,184.21-₹337.25
Total Cash Flow₹2,624.04₹559.93-₹248.05₹273.22
Cash (Start of the year)₹1,543.69₹983.76₹1,231.81₹991.37
Cash (End of the year)₹4,167.73₹1,543.69₹983.76₹1,264.59

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹14,337.45₹12,406.30₹10,549.53₹10,504.63
Current Assets₹24,027.38₹16,798.58₹13,447.65₹12,451.30
Total Assets₹38,364.83₹29,204.88₹23,997.18₹22,955.93
Current Liabilities₹12,651.24₹8,961.39₹8,501.50₹9,265.37
Net Current Asset₹11,376.14₹7,837.19₹4,946.15₹3,185.93
Non-Current Liabilities₹3,200.22₹2,949.14₹1,122.23₹1,147.74
Equity Capital₹22,513.37₹17,294.35₹14,373.45₹12,542.82
Total Equity & Liabilities₹38,364.83₹29,204.88₹23,997.18₹22,955.93

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹19,512.66₹16,967.50₹14,666.50₹11,258.83
Other Income₹939.87₹253.39₹115.51₹210.02
Total Revenue₹20,452.53₹17,220.89₹14,782.01₹11,468.85
Total Expenses₹13,164.85₹12,306.55₹11,997.32₹10,941.71
Profit Before Tax₹7,694.25₹4,837.12₹2,784.69₹527.14
Tax₹1,327.69₹864.16₹458.60₹101.93
Profit After Tax₹6,366.56₹3,972.96₹2,326.09₹425.21
EPS - Basic₹139.38₹87.10₹51.10₹9.35
EPS - Diluted₹139.01₹86.79₹50.87₹9.31

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹7,694.25₹4,837.12₹2,784.69₹527.14
Income before WC changes₹7,357.46₹5,549.24₹3,555.99₹1,110.93
Change in Assets-₹1,343.64-₹2,041.95-₹1,597.72₹529.00
Change in Liabilities₹681.90-₹254.45₹692.51₹280.86
Change in WC-₹661.74-₹2,296.40-₹905.21₹809.86
Cash flow from Operations₹5,539.85₹2,444.65₹2,504.13₹1,793.99
Cash flow from Investing-₹5,648.89-₹1,766.32-₹1,599.02-₹1,269.17
Cash flow from Financing-₹121.13-₹460.23-₹867.07-₹498.26
Total Cash Flow-₹230.17₹218.10₹38.04₹26.56
Cash (Start of the year)₹341.80₹123.70₹85.66₹59.10
Cash (End of the year)₹111.63₹341.80₹123.70₹85.66

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹20,507.83₹16,537.44₹15,634.99₹15,112.75
Current Assets₹15,595.06₹11,894.55₹9,287.87₹7,570.92
Total Assets₹36,102.89₹28,431.99₹24,922.86₹22,683.67
Current Liabilities₹4,832.33₹3,299.74₹3,693.94₹3,627.85
Net Current Asset₹10,762.73₹8,594.81₹5,593.93₹3,943.07
Non-Current Liabilities₹1,136.79₹854.01₹625.83₹643.96
Equity Capital₹30,133.77₹24,278.24₹20,603.09₹18,411.86
Total Equity & Liabilities₹36,102.89₹28,431.99₹24,922.86₹22,683.67
* All values are in INR Crore
Lupin market depth
Bid quantityBid priceAsk priceAsk quantity
7819811981.73
541980.91982.2125
751980.81982.3178
1161980.71982.457
1741980.61982.531
Total bid quantity497
Total ask quantity394
Lupin technical summary
Bearish indicators2
Neutral indicators5
Bullish indicators1
OverallSlightly Bearish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
50.82
Neutral
ATR (14)
41.56
Neutral
STOCH(9,6)
68.38
Neutral
STOCH RSI (14)
92.87
Bearish
ADX(9)
34.63
Bearish
UO(9)
54.3
Neutral
ROC(12)
2.4
Bullish
WillR(14)
-31.62
Neutral
Period
Simple value
Exponential vaue
5D
2004.38
2000.6
10D
1975.74
1988.68
20D
1967.56
1991.61
50D
2050.21
2058.63
100D
2213.15
2142.84
Volume trend — traded volume by day
5 Nov4L
4 Nov17L
3 Nov10L
2 Nov6L
30 Oct7L
29 Oct7L
Average8L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Lupin
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Lupin

Fund name
AUM
Tata Nifty MidSmall Healthcare Index Fund
10.41%
Motilal Oswal Nifty MidSmall Healthcare Index Fund
10.25%
Nippon India Pharma Fund
7.99%

Lupin Returns Calculator

Ex-date: 17 Jul 2026

Lupin Latest News

1 day ago
Stocks to watch, Nov 4: Lupin, NSE, BSE, Nykaa, PFC, Premier Energies, Waaree Energies, Yatharth Hospital
2 days ago
Q2 results, Nov 3: SBI, NSE, Bajaj Finserv, Solar Industries, Lupin, MCX, Graphite India, Gujarat Fluorochemicals, GSK, others to post earnings
2 days ago
Stocks to watch, Nov 3: Lupin, ITC, Marico, NBCC, SBI, NSE, VMS TMT, Samvardhana Motherson, PTC India
1 month ago
Sun Pharma, Mankind Pharma, Wockhardt, other pharma stocks surge up to 6%, Nifty Pharma up 1.5%; key things to know
1 month ago
Stocks to watch, September 7: Tata Motors, oil-linked stocks, SBI, IFCI, Lupin, NMDC, HUL, IndusInd Bank
3 months ago
Q1 Results: LIC, Trent, Britannia, HeroMoto Corp, Lupin, Premier Energies, Prime Focus, others to post earnings on Aug 6
3 months ago
Sun Pharma, Cipla, other pharma stocks decline as Trump unveils steep tariff plan on generic drugs: Key FAQs answered
3 months ago
Balaji Amines, Aequs, Nykaa, Sun Pharma among 70 stocks at 52-week highs in weak market; check full list
4 months ago
Lupin partners with Spanish pharma company for launch of Luforbec inhalers in Spain; check stock performance
5 months ago
Stocks to watch, June 5: Rate-sensitives, Lupin, CG Power, Aurobindo Pharma, Hindalco, Ola Electric
Showing news item 1 of 10

Top Gainers

ASHOKLEY Share Price
₹170.31
+16.28 (+10.57%)
FIVESTAR Share Price
₹433.15
+36 (+9.06%)
M&MFIN Share Price
₹292.40
+22.3 (+8.26%)
PRINCEPIPE Share Price
₹320.30
+22.55 (+7.57%)
BALKRISIND Share Price
₹2407.80
+164.1 (+7.31%)
See more

Top Losers

PIIND Share Price
₹1870.10
-316.9 (-14.49%)
CUMMINSIND Share Price
₹4230.60
-495.1 (-10.48%)
APTUS Share Price
₹185.15
-21.13 (-10.24%)
GMMPFAUDLR Share Price
₹1201.80
-118.4 (-8.97%)
OIL Share Price
₹435.10
-22.9 (-5%)
See more

Lupin Share Price FAQs

Please be aware that Lupin stock prices are subject to continuous fluctuations due to various factors.